DrugCite
Search

OPTIMARK

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Optimark Adverse Events Reported to the FDA Over Time

How are Optimark adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Optimark, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Optimark is flagged as the suspect drug causing the adverse event.

Most Common Optimark Adverse Events Reported to the FDA

What are the most common Optimark adverse events reported to the FDA?

Nephrogenic Systemic Fibrosis
2411 (8.04%)
Pain
1554 (5.18%)
Anxiety
909 (3.03%)
Emotional Distress
855 (2.85%)
General Physical Health Deteriorati...
817 (2.72%)
Fibrosis
755 (2.52%)
Mobility Decreased
754 (2.51%)
Scar
692 (2.31%)
Injury
628 (2.09%)
Oedema Peripheral
609 (2.03%)
Skin Induration
602 (2.01%)
Show More Show More
Skin Tightness
582 (1.94%)
Skin Hypertrophy
578 (1.93%)
Joint Range Of Motion Decreased
495 (1.65%)
Skin Fibrosis
495 (1.65%)
Deformity
450 (1.5%)
Pain In Extremity
371 (1.24%)
Anhedonia
342 (1.14%)
Musculoskeletal Stiffness
338 (1.13%)
Joint Stiffness
315 (1.05%)
Skin Discolouration
315 (1.05%)
Joint Contracture
298 (.99%)
Off Label Use
285 (.95%)
Pruritus
280 (.93%)
Muscular Weakness
273 (.91%)
Erythema
271 (.9%)
Arthralgia
270 (.9%)
Skin Hyperpigmentation
247 (.82%)
Gait Disturbance
230 (.77%)
Asthenia
205 (.68%)
Dry Skin
205 (.68%)
Skin Exfoliation
202 (.67%)
Extremity Contracture
194 (.65%)
Hypoaesthesia
179 (.6%)
Skin Disorder
176 (.59%)
Pain Of Skin
171 (.57%)
Oedema
170 (.57%)
Depression
165 (.55%)
Skin Plaque
161 (.54%)
Rash
152 (.51%)
Fatigue
144 (.48%)
Skin Lesion
131 (.44%)
Back Pain
130 (.43%)
Muscle Tightness
119 (.4%)
Skin Ulcer
118 (.39%)
Muscle Contracture
116 (.39%)
Burning Sensation
113 (.38%)
Abasia
111 (.37%)
Myalgia
100 (.33%)
Dyspnoea
98 (.33%)
Nausea
98 (.33%)
Pneumonia
94 (.31%)
Paraesthesia
90 (.3%)
Cardiac Failure Congestive
87 (.29%)
Fall
87 (.29%)
Joint Swelling
87 (.29%)
Bone Pain
82 (.27%)
Insomnia
79 (.26%)
Motor Dysfunction
79 (.26%)
Vomiting
79 (.26%)
Chest Pain
77 (.26%)
Rash Macular
75 (.25%)
Rash Papular
74 (.25%)
Drug Prescribing Error
73 (.24%)
Quality Of Life Decreased
69 (.23%)
Anaemia
67 (.22%)
Swelling
67 (.22%)
Pruritus Generalised
66 (.22%)
Cellulitis
65 (.22%)
Skin Swelling
65 (.22%)
Skin Burning Sensation
64 (.21%)
Activities Of Daily Living Impaired
57 (.19%)
Skin Fissures
56 (.19%)
Dysstasia
53 (.18%)
Abdominal Pain
51 (.17%)
Renal Failure Chronic
51 (.17%)
Diarrhoea
50 (.17%)
Pleural Effusion
49 (.16%)
Discomfort
48 (.16%)
Pyrexia
48 (.16%)
Cerebrovascular Accident
47 (.16%)
Confusional State
46 (.15%)
Exfoliative Rash
46 (.15%)
Fluid Overload
45 (.15%)
Pulmonary Hypertension
45 (.15%)
Atrial Fibrillation
44 (.15%)
Cough
44 (.15%)
Hyperkeratosis
44 (.15%)
Constipation
42 (.14%)
Headache
42 (.14%)
Muscle Spasms
41 (.14%)
Myosclerosis
41 (.14%)
Respiratory Failure
40 (.13%)
Tremor
39 (.13%)
Hypotension
38 (.13%)
Upper Respiratory Tract Infection
37 (.12%)
Hypertension
35 (.12%)
Osteoarthritis
35 (.12%)
Subcutaneous Nodule
35 (.12%)
Rash Pruritic
34 (.11%)
Urinary Tract Infection
34 (.11%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Optimark, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Optimark is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Optimark

What are the most common Optimark adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Optimark, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Optimark is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Optimark According to Those Reporting Adverse Events

Why are people taking Optimark, according to those reporting adverse events to the FDA?

Nuclear Magnetic Resonance Imaging
1663
Angiogram
304
Nuclear Magnetic Resonance Imaging ...
219
Imaging Procedure
125
Drug Use For Unknown Indication
122
Product Used For Unknown Indication
98
Show More Show More
Nuclear Magnetic Resonance Imaging ...
47
Diagnostic Procedure
35
Ventricular Dysfunction
14
Fistulogram
13
Arteriogram
12
Scan
11
Headache
11
Venogram
11
Disorientation
9
Arthrogram
9
Muscular Weakness
9
Computerised Tomogram
8
Coronary Artery Disease
6
Arteriogram Coronary
6
Nuclear Magnetic Resonance Imaging ...
5
Renal Abscess
4
Renal Mass
4
Transplant Evaluation
3
Venous Thrombosis
3
Arteriogram Renal
3
Scan With Contrast
3
Back Pain
2
Joint Deposit
2
Angiogram Cerebral
2
Dizziness
2
Cardiac Pharmacologic Stress Test
1
Chest Pain
1
Deafness Unilateral
1
Tendonitis
1
Amnesia
1
Neoplasm Malignant
1
Post Procedural Stroke
1
Brain Injury
1
Cerebrovascular Disorder
1
Renal Scan
1
Myocardial Infarction
1

Drug Labels

LabelLabelerEffective
OptimarkMallinckrodt Inc. 18-APR-11
OptimarkMallinckrodt Inc.09-MAR-13
OptimarkMallinckrodt Inc.09-MAR-13

Optimark Case Reports

What Optimark safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Optimark. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Optimark.